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There were an estimated 370,000 AIDS 
deaths in South Africa in 2003 alone. 
It is, therefore, not surprising that the 
apparent reluctance of the South African 
government to support the provision of 
antiretroviral treatment to people with 
HIV/AIDS has been the subject of much 
controversy internationally. The situation 
is, however, changing, and South Africa is 
now seeing a scaling up of access to highly 
active antiretroviral therapy (HAART) and 
a gradual reduction in HAART prices.
HAART, nevertheless, remains an 
expensive option, and one that many 
low-income countries are unable to 
afford. South Africa is better placed than 
most sub-Saharan nations to increase 
access to HAART, but it is clearly essential 
to establish how much this will cost the 
country’s public health sector and what 
will be the beneﬁ  ts. It is unfortunate, 
therefore, that cost-effectiveness studies 
on HAART have so far been limited to the 
developed world. 
In the January issue of PLoS Medicine,
Motasim Badri and colleagues publish a 
study of the use of the cost-effectiveness 
of HAART conducted in South Africa. 
During the study period (January 1995 
to December 2000), HAART was not 
available in the publicly funded South 
African health-care sector. The research 
was funded by Secure the Future—a 
Bristol-Myers Squibb initiative to provide 
resources for capacity building and for 
the search for sustainable interventions 
to address HIV/AIDS in sub-Saharan 
Africa— and took place in HIV clinics 
afﬁ  liated to the University of Cape Town. 
The sponsors had no involvement in 
the study design, analysis, or decision 
to publish. The study was based on a 
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In the developed world, age-related macular degeneration 
(AMD) is the most common cause of blindness in later life—in 
the United States, for example, it affects around 15 million 
people. Early signs of AMD in the retina are pigmentation and 
soft drusen deposits of protein, fat, and cellular debris. Advanced 
AMD was previously classiﬁ  ed into wet and dry types; dry AMD, 
now known as geographic atrophy (GA) or atrophic AMD, occurs 
as the light-sensing cells (photoreceptors) in the macula break 
down. Wet AMD, now known as neovascular or exudative AMD, 
is caused when abnormal, fragile blood vessels grow under the 
macula, underneath the retina. These blood vessels often leak 
blood, lipid, and ﬂ  uid, which lift the macula. 
Late (sight-threatening) AMD is found in about 2% of all 
people over 50 years of age, and the incidence of the disease 
rises with age, occurring in 0.7%–1.4% of people aged 65–75 
years, and in 11%–19% of people over 85 years of age. The 
neovascular form can rapidly lead to severe blindness, whereas 
the atrophic form progresses more slowly. Although age is the 
main risk factor for AMD, hypertension, smoking, and a family 
history of AMD also increase risk of developing the disease. 
Previous genetic linkage studies have suggested that a locus 
on the long arm of Chromosome 1 was involved in AMD’s 
pathogenesis. Further studies, then, reﬁ  ned these analyses and 
showed that a variant in one gene, Complement Factor H (CFH),
was present more frequently in people with advanced AMD 
than in normal controls. A paper in PLoS Medicine now takes this 
genetic analysis further, asking whether this same variant is also 
associated with early AMD.
The investigators, from Iceland and the US, looked at 
two cohorts of patients with advanced and early AMD, and 
compared them with controls. They conﬁ  rmed previous work 
on the association of the CFH variant with advanced AMD, but 
furthermore showed that the same variant was associated 
with soft drusen and also equally with both forms of advanced 
AMD. The implications of these ﬁ  ndings are that CFH would 
seem to have a role early in the development of AMD, and that 
other genes or environmental factors are likely to determine 
which patients will progress to late AMD, and if so, which type 
of AMD. This role would ﬁ  t in with what is known about CFH. 
CFH is a serum glycoprotein that controls the function of the 
alternative complement pathway and acts as a cofactor with 
factor I (C3b inactivator). Family syndromes have been described 
in which deﬁ  ciency of CFH leads to spontaneous activation of 
the alternative pathway. The variation associated with AMD 
causes a milder phenotype, but may attenuate the complement 
inhibitory function of CFH, making complement attack of retinal 
pigmented epithelial and choroidal cells via the alternative 
pathway more likely. 
Ultimately, work such as this that dissects out genetic risk 
factors for diseases are of most value when they suggest, as here, 
a pathway for targeting, in a disease with few treatment options 
once the disease is established.
Magnusson KP, Duan S, Sigurdsson H, Petursson H, Yang Z, et al. 
(2006) CFH Y402H confers similar risk of soft drusen and both forms 
of advanced AMD. DOI: 10.1371/journal.pmed.0030005
Pinpointing the Earliest Defects in Age-Related Macular Degeneration 
DOI: 10.1371/journal.pmed.0030038
DOI: 10.1371/journal.pmed.0030038.g001
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prospective cohort study—the Cape 
Town AIDS Cohort (CTAC).
The researchers compared the cost of 
services for 292 patients who were given 
HAART with the costs for a matched 
comparison group (with the same 
number of patients) who were not given 
any antiretroviral drugs. Twenty-seven 
patients in each group had AIDS; the 
others were HIV-infected but did not 
have AIDS. The researchers calculated 
costs per patient year (PPY) and per 
life-year gained (LYG)—i.e., the total cost 
divided by the number of extra years the 
treated patients lived. Calculations were 
done separately for patients with AIDS 
and for those without AIDS. 
Patients on HAART required fewer 
hospital admissions. Depending on how 
long the patient survived and the price 
of antiretrovirals used, HAART reduced 
treatment costs for those patients with 
AIDS. For this group, the cost savings 
ranged from US$219–US$2,116. For 
patients without AIDS, the yearly cost 
of treatment (ranging from US$597–
US$1,772) was, in the opinion of the 
authors, and after taking into account the 
South African standard of cost of living, 
considered to be affordable. However, it 
is expected that South Africa will soon 
be able to manufacture antiretroviral 
drugs locally and more cheaply. This 
would increase the amount saved by 
introducing HAART.
The study had a number of limitations. 
Because HAART was not used in routine 
clinical practice, the researchers had to 
compare a group of patients enrolled in 
clinical trials with a control group that 
was not part of the trials. The study was 
also conﬁ  ned to the use and cost of 
services; but when a person is infected 
with HIV and becomes ill or dies from 
AIDS, it is clearly not only the health 
services that face costs. The patient, their 
family, and the country suffer ﬁ  nancially. 
HAART, as a more effective treatment 
might also lower these “indirect” costs, 
but this was not an issue examined 
here. It is to be hoped that further 
research includes an evaluation of the 
indirect costs and beneﬁ  ts. Nevertheless, 
the present study should encourage 
policymakers in low- and middle-income 
countries to consider introducing HAART 
into public-sector health care; reductions 
in the use of hospital services by patients 
with HIV could free scarce resources, 
to the beneﬁ  t of all who use the health 
services.
Badri M, Maartens G, Mandalia S, 
Bekker LG, Penrod JR, et al. (2006) Cost-
Effectiveness of Highly Active Antiretroviral 
Therapy in South Africa. DOI: 10.1371/
journal.pmed.0030004
An HIV vaccine still seems to be a long 
way off, but scientists are pursuing several 
lines of research that could limit HIV 
infection. Increasing evidence indicates 
that the host’s natural immunity has a 
major, albeit usually insufﬁ  cient, role in 
limiting HIV-1 infection. Most efforts at 
stimulating an immune response have 
been disappointing and have underscored 
the inability of natural immune responses 
to control HIV-1 infection in most infected 
or immunized individuals. Strategies to 
develop a vaccine include the stimulation 
of immune responses by manipulating 
HIV antigens and delivery systems, and 
by using various adjuvants. One way to 
achieve an effective immune response 
to prevent or control HIV infection may 
be through exploiting the potential of 
dendritic cells to modulate the immune 
system. Dendritic cells mediate innate and 
adaptive immunity against viral infection 
by providing proinﬂ  ammatory cytokines 
and by processing and presenting 
antigens to T cells.
Now, Xiao-Tong Song, Si-Yi Chen, and 
colleagues suggest that a molecule 
that helps regulate dendritic cells can 
help control not only HIV-speciﬁ  c CD8+
cytotoxic T lymphocytes (CTLs) and 
CD4+ T helper cells but also antibody 
responses. CD8+ cytotoxic T cells are the 
main mediators of viral control, and there 
is a growing consensus that an effective 
HIV immunization approach should be 
capable of inducing vigorous protective 
CTLs, as well as antibody responses. Song 
and colleagues suggest that a molecule, 
the suppressor of cytokine signaling 
(SOCS) 1, a negative regulator of the Janus 
kinase/signal transducer and activator-
of-transcription (JAK/STAT) pathway in 
dendritic cells, attenuates cellular signaling 
in HIV-1 infection. The team has previously 
noted that SOCS1 helped regulate antigen 
presentation by dendritic cells, and SOCS1-
silenced dendritic cells induced enhanced 
CTL responses against tumor-associated 
antigens.
In a new study, Song and colleagues 
found that in mice SOCS1-restricted 
signaling not only controlled the 
production of proinﬂ  ammatory cytokines 
such as IL-12 by dendritic cells but 
also had a critical role in regulating 
the anti-HIV immune response. 
SOCS1-silenced dendritic cells were 
resistant to HIV envelope-mediated 
suppression and effectively induced a 
memory response, with HIV envelope-
speciﬁ  c antibody and T cell responses. 
Furthermore, the potency of the HIV DNA 
vaccination was signiﬁ  cantly enhanced 
by coimmunization with SOCS1 small 
interfering RNA (siRNA) expressor DNA. 
Although the mechanism behind this 
response is unclear, it may involve the 
enhanced production of a mixed pattern 
of Th1- and Th2-polarizing cytokines by 
SOCS1-silenced dendritic cells.
The ﬁ  ndings suggest that a balanced 
memory humoral and cellular response 
against HIV could be induced by 
SOCS1-silenced dendritic cells and 
SOCS1-siRNA DNA. This SOCS1 silencing 
strategy could help enhance therapeutic 
and prophylactic vaccines against HIV 
and other pathogens. When used with 
improved HIV immunogens and delivery 
systems, this vaccination approach may 
provide a new avenue to enhance weak 
protective immune responses or to 
generate broader and stronger responses 
not only against dominant epitopes but 
also against weakly immunogenic or 
cryptic, yet protective, epitopes.
Song XT, Evel-Kabler K, Rollins L, Aldrich 
M, Gao F, et al. (2006) An alternative and 
effective HIV vaccination approach based 
on inhibition of antigen presentation 
attenuators in dendritic cells. DOI: 10.1371/
journal.pmed.0030011
Taking an Alternative Approach to HIV Vaccination 
DOI: 10.1371/journal.pmed.0030058
DOI: 10.1371/journal.pmed.0030058.g001
Lentiviral transduced dendritic cells.
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Infectious disease modeling has 
a long history, going back to at least 
Daniel Bernouli’s smallpox model from 
1760. The discipline is driven by the 
desire to understand the dynamics of 
an outbreak or epidemic in order to 
plan control strategies. The hope is that 
better models will also allow prediction 
of future outbreaks, and inform not 
just preparedness but also prevention 
strategies. One critical component of all 
infectious disease models—and by some 
experts seen as the bottleneck of most 
models—is the mode of transmission. 
Interaction between modelers and 
experimentalists who study transmission 
from environment to humans and 
transmission between humans is 
therefore crucial.
In 2002, Andrew Camilli and 
colleagues reported that passage 
through a human host potentiated 
the infectivity of the cholera pathogen 
Vibrio cholerae (Nature 417: 642–645). 
They isolated and characterized V.
cholerae from human stools, and found 
that passage through the human 
gastrointestinal tract induces a transient 
hyperinfectious state in the bacteria, 
which is perpetuated for a number of 
hours, even outside the human host. 
(Infectiousness was determined in 
competition assays in infant mice.) This 
hyperinfectious state was associated 
with speciﬁ  c gene expression proﬁ  les 
that differed from those of bacteria in 
their normal aquatic reservoirs. 
The study caught the attention of 
David Hartley and colleagues, who saw 
a chance to improve modeling in the 
field of cholera epidemics. Hartley was 
interested because Camilli’s results 
shed new light on a fundamental 
question in cholera epidemiology, 
namely, what is the relative importance 
of human-to-human (i.e., fecal to oral) 
versus environment-to-human infection 
(through contaminated food or 
water)? If the infective dose of bacteria 
that have become hyperinfectious 
because of recent passage through 
a human host is lower than that of 
environmental V. cholerae, this would 
support a crucial role of human-to-
human transmission in the generation 
of cholera epidemics. 
Hartley and colleagues found that 
incorporation of the existence of a 
hyperinfectious state into their disease 
models resulted in a much better ﬁ  t 
of the predictions with the observed 
explosive epidemic patterns of past 
cholera outbreaks. On one hand, this 
result lends theoretical support for 
Camilli’s results and suggests that his 
ﬁ  ndings in laboratory animals have 
clinical relevance. On the other hand, 
it strongly suggests that human-to-
human transmission is crucial for 
cholera epidemics and pandemics, and 
that health measures must focus on 
minimizing risk of transmission of the 
short-lived hyperinfectious form of V.
cholerae that results from transmission 
through a human host. Finally, there is 
the intriguing possibility that similar 
hyperinfectious states exist for other 
bacteria, something that seems well 
worth exploring. 
Hartley DM, Morris JG Jr, Smith DL (2006) 
Hyperinfectivity: A critical element in the 
ability of V. cholerae to cause epidemics? 
DOI: 10.1371/journal.pmed.0030007
Adjusting Cholera Models to Recent Experimental Data
DOI: 10.1371/journal.pmed.0030028
Systemic sclerosis (SSc) is an autoimmune disease characterized 
by structural and functional vascular abnormalities, immunologic 
changes, and excessive extracellular matrix deposition, leading to 
ﬁ  brosis of the skin and the internal organs. The activation of the 
immune system is vital in the pathogenesis of SSc. Autoantibodies 
directed against cell surface antigens are believed to induce 
endothelial cell damage and apoptosis, which are thought to be 
a primary event in the pathogenesis of the disease, leading to a 
cascade of stimulatory changes involving many cells, including 
ﬁ  broblasts, T lymphocytes, and macrophages. In turn, these 
activated cells secrete substances, including cytokines and 
their soluble receptors, and enzymes and their inhibitors. These 
substances lead to changes in the extracellular matrix compounds, 
including ﬁ  bronectin, proteoglycans, and collagen types I, III, V, and 
VII; speciﬁ  cally TGF-beta, interleukin-4 (IL-4), and platelet-derived 
growth factor are proﬁ  brotic cytokines.
Environmental factors may be involved in the disease’s 
pathogenesis. Previous research has shown that a molecular 
mimicry mechanism links antibodies against the human 
cytomegalovirus (hCMV)-derived protein UL94 to the 
CMV and Triggers of Systemic Sclerosis
DOI: 10.1371/journal.pmed.0030045
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Cytomegalovirus in the pathogenesis of systemic sclerosis.
DOI: 10.1371/journal.pmed.0030028.g001
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Epidemiologists have used mathematical models to predict 
and understand the dynamics of infectious diseases for more 
than 100 years. The emergence of diseases such as ebola, 
severe acute respiratory syndrome (SARS), West Nile virus, and 
multidrug-resistant malaria; incidences of bioterrorism; and most 
recently, the threat of a bird ﬂ  u pandemic have attached even 
greater importance to this management tool. Models are used 
to provide information on the infection and to predict the effect 
of courses of action. The World Health Organization has said 
that the primary goals of any early warning system should be to 
predict the timing and magnitude of an outbreak. But it has said 
that forecasting will save the most lives when it can accurately 
predict the ﬁ  nal size of the outbreak. 
However, researchers admit that predicting the ﬁ  nal size of 
an outbreak is notoriously difﬁ  cult. For example, even for annual 
events such as meningitis outbreaks in West Africa, researchers 
still ﬁ  nd it hard to predict the ﬁ  nal size of the epidemic. Of course, 
mathematical models, whether in epidemiology or otherwise, are 
only as good as the assumptions on which they are based. So if 
a model makes predictions out of line with observed results and 
the calculations are correct, the initial assumptions that made 
the model useful must be changed. 
In PLoS Medicine, John Drake investigates the limits of 
forecasting precision for directly transmitted diseases, and 
suggests epidemiologists shouldn’t focus exclusively on the 
ﬁ  nal size of an outbreak. He says the stochastic (chance) contact 
process by which outbreaks develop creates fundamental limits 
for the precision with which the ﬁ  nal size of the outbreak can be 
predicted.
Drake modeled the expected ﬁ  nal outbreak size in nine well-
studied infectious diseases (chicken pox, diphtheria, measles, 
mumps, poliomyelitis, rubella, scarlet fever, smallpox, and 
whooping cough). He then applied his ﬁ  ndings to a new model, 
a simple stochastic epidemic with delayed onset intervention, 
which represents actual outbreaks of emerging infections more 
realistically. He found that the ﬁ  nal size of an outbreak is difﬁ  cult 
to predict because of local environmental and disease-speciﬁ  c 
conditions. Also, outbreak dynamics are very susceptible to the 
seemingly random sequence of infectious contacts and the early 
removal of infectious patients from the unobserved stages of the 
outbreak.
The basic approach currently used by epidemiologists is 
to compare the average of the inﬂ  uencing factors with the 
basic reproductive ratio of the disease. This approach is ﬁ  ne for 
early warning systems, but for emerging diseases or sudden 
outbreaks, the ﬁ  nal outbreak size can differ greatly from these 
straightforward calculations. 
Drake says that a stochastic theory of epidemics, which 
accounts for probable changes, can better quantify whether 
an outbreak size can deviate from initial calculations and can 
account for changing removal rate and/or number of infectious 
contacts. He found that in epidemics the coefﬁ  cient of variation 
in the ﬁ  nal outbreak size was greater than one for outbreaks 
where the removal rate was less than about 2.41 times the 
contact rate. The removal rate changes when clinicians are able 
to increase their ability to diagnose and treat infected patients, 
he suggests. And, he says, the number of infectious contacts 
falls when the rising number of cases dilutes the remaining 
susceptible population. When testing these observations in a 
representative example, Drake found that the average outbreak 
size grew exponentially with the delay between the start of 
the outbreak and the implementation of the intervention, 
underscoring the importance of rapid intervention.
His ﬁ  ndings stressed the point that rapidly starting control 
measures was important not only for controlling the ﬁ  nal 
outbreak size but also for decreasing the variation in the ﬁ  nal 
size of the outbreak. And epidemiologists should not just 
focus on predicting outbreak size, but also consider other 
characteristics, such as the timing of disease emergence.
Drake JM (2006) Limits to forecasting precision for outbreaks of 
directly transmitted diseases. DOI: 10.1371/journal.pmed.0030003
The Difﬁ  culties of Predicting the Outbreak Sizes of Epidemics 
DOI: 10.1371/journal.pmed.0030023
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pathogenesis of SSc. The UL94 epitope shows homology with 
NAG-2, a surface molecule highly expressed on endothelial 
cells. Anti-UL94 peptide antibodies have been shown to induce 
apoptosis of endothelial cells upon engagement with the NAG-
2-integrin complex.
In a new study, Claudio Lunardi and colleagues examined 
further whether hCMV could be involved in the pathogenesis 
of ﬁ  brosis, and also attempted to dissect out the molecular 
mechanisms behind the disease. They found that NAG-2 was also 
expressed on dermal ﬁ  broblasts, and that anti-UL94 antibodies 
bind to ﬁ  broblasts. 
Using gene arrays, they analyzed the transcriptional proﬁ  le 
in endothelial cells and dermal ﬁ  broblasts in response to 
treatment with antibodies against the UL94 peptide. Exposure of 
endothelial cells to anti-UL94 antibodies had a profound impact 
on gene expression, resulting in the upregulation of 1,645 
transcripts. The genes altered encoded for adhesion molecules, 
chemokines, colony-stimulating factors, growth factors, and 
molecules involved in apoptosis. Dermal ﬁ  broblasts showed an 
upregulation of 989 transcripts and acquired a “scleroderma-like” 
phenotype, with upregulation of genes involved in extracellular 
matrix deposition, growth factors, chemokines, and cytokines. 
To conﬁ  rm these ﬁ  ndings, the investigators measured the 
levels of chemokines, cytokines, growth factors, and collagen 
type I in the supernatants of stimulated and unstimulated cells. 
They found that the concentration of the molecules was higher 
in the cells incubated with anti-hCMV antibodies, conﬁ  rming that 
genes’ upregulation was paralleled by the induction of protein 
synthesis.
Taking this analysis further into patients, the investigators 
measured the serum concentrations of some cytokines, 
chemokines, and adhesion molecules in patients and controls, 
and conﬁ  rmed that the genes found overexpressed in vitro 
following stimulation with anti-hCMV antibodies could indeed 
be of relevance in vivo.
Altogether, these ﬁ  ndings suggest that these cross-reacting 
antivirus antibodies were able to induce not only endothelial 
cell activation and apoptosis but also ﬁ  broblast activation. 
They could thus be a single trigger of the two hallmarks of SSc, 
vascular damage and ﬁ  brosis.
Lunardi C, Dolcino M, Peterlana D, Bason C, Navone R, et al. (2006) 
Antibodies against human cytomegalovirus in the pathogenesis of 
systemic sclerosis: A gene array approach. DOI: 10.1371/journal.
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calculate a risk score, and showed that it 
predicted patient survival independent 
of clinical parameters. They suggest that 
combining this risk score with tumor 
grade, stage, and patient performance 
status might help to identify patients 
with RCC who have a high probability 
of being cured and need less intensive 
adjuvant treatment and follow-up testing 
after surgery, as well as those who should 
receive more aggressive treatment. 
The next step will be to test the value 
of the risk score in independent studies. 
To be able to determine expression 
proﬁ  les in routine clinical settings, it will 
also be necessary to further reduce the 
number of genes in the prognostic set. 
Brooks et al. ﬁ  nd that as few as four genes 
from their prognostic set can estimate 
outcome. They acknowledge that 
“application of the [supervised principal 
components] risk score in the clinical 
setting will depend on independent 
conﬁ  rmation of [their] ﬁ  ndings,” but 
conclude “that it should be possible to 
develop clinically useful predictors of 
survival based on these technologies.” 
Zhao H, Ljungberg B, Grankvist K, 
Rasmuson T, Tibshirani R, et al. (2006) 
Gene expression proﬁ  ling predicts survival 
in conventional renal cell carcinoma. DOI: 
10.1371/journal.pmed.0030013
Nearly 95,000 people worldwide 
die from kidney cancer every year, and 
renal cell carcinoma (RCC) accounts for 
most of the deaths. Surgery can cure 
60%–70% of patients with localized 
disease and prolong survival in patients 
with metastatic disease, but survival 
rates after treatment have not improved 
appreciably over the past 30 years.
Current survival estimates based on 
clinical characteristics such as tumor 
size and grade are not very accurate, 
and the varied response to surgery and 
other treatments suggests an underlying 
diversity that is not captured by the 
clinical parameters. As has been the case 
for other cancer types, researchers hope 
that comprehensive molecular genetic 
analysis will reveal distinguishing features 
that could serve as prognostic indicators, 
improve outcome prediction, and inform 
treatment decisions. Several previously 
reported expression-proﬁ  ling studies of 
relatively small sets of RCCs suggested 
that comprehensive molecular genetic 
analysis might be useful in this cancer 
type as well. 
To further the understanding of 
the genetics and molecular biology 
underlying RCC, James Brooks and 
colleagues determined the gene 
expression patterns of a set of 177 
tumors from patients with detailed 
clinical information available, including 
long-term follow-up. Based on the results, 
the researchers could divide the tumors 
into ﬁ  ve distinct subgroups, which 
differed in the expression patterns of over 
3,000 genes. These subgroups correlated 
with survival after nephrectomy. The 
correlation was independent of tumor 
stage and grade, suggesting that 
molecular and genetic changes early 
during tumorigenesis determine the 
characteristics of a particular cancer and 
can be used to predict clinical outcome. 
Brooks and colleagues then used 
a computational tool to identify 259 
genes for which expression status was 
highly predictive of clinical outcome. The 
genes in this prognostic set represent a 
range of molecular pathways, and map 
to different parts of the genome. They 
found that 95% of them are expressed at 
high levels in tumors of patients with a 
good prognosis and at low levels in more 
aggressive cancers. 
In an independent group of patients, 
the researchers used these 259 genes to 
Expression Proﬁ  ling Predicts Survival in Kidney Cancer
DOI: 10.1371/journal.pmed.0030035
DOI: 10.1371/journal.pmed.0030035.g001
A group of renal cell carcinomas share similar expression patterns.
Mother-to-child transmission (MTCT) 
is the predominant way that children 
become infected with HIV. MTCT can 
occur prenatally during pregnancy, 
perinatally during labor and delivery, 
and postnatally through breastfeeding. 
In the absence of speciﬁ  c interventions, 
approximately one-third of children 
born to mothers who are HIV-positive 
become infected themselves. Speciﬁ  c 
interventions, including prenatal HIV 
counseling and testing, antiretroviral 
prophylaxis, elective cesarean delivery, 
and avoidance of breastfeeding, have 
reduced MTCT to less than 2% in 
developed countries. In many less-
developed countries, however, these 
interventions are not readily available, 
and even effective, shorter, and cheaper 
antiretroviral prophylaxis strategies 
have not yet been widely implemented 
or accepted. As a result, MTCT rates in 
lower-income countries remain high, 
accounting for an estimated 2,000 new 
pediatric HIV infections per day. 
An estimated one-half of the infant 
infections occur during labor and 
delivery, but the exact mechanisms 
remain poorly understood. Two possible 
ways of transmission have been 
proposed: direct contact of infant mucosa 
with HIV-infected maternal body ﬂ  uids, 
and placental microtransfusions after 
breakdown of the maternal–fetal barrier 
through contractions at the beginning of 
labor. However, the evidence implicating 
either transmission route has been 
inconclusive. 
Placental Microtransfusions Associated with Increased HIV 
Transmission from Mother to Child
DOI: 10.1371/journal.pmed.0030026
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Glioblastoma multiforme (GBM) 
develops in the tissue of the brain and 
grows quickly, often becoming very large 
before a person experiences symptoms 
and is diagnosed. Surgery is done to 
remove as much of the tumor as possible, 
and followed with radiation and/or 
chemotherapy to slow progression of the 
disease. But despite aggressive treatment, 
the cancer almost inevitably recurs, and 
patients usually die within a year.
Researchers are studying several 
ways to treat GBM using gene therapy. 
Some approaches target healthy cells 
to enhance their ability to ﬁ  ght cancer; 
others target cancer cells to destroy them 
or prevent their growth. Researchers 
are also experimenting with immune 
therapies, which seek to restore and 
stimulate the body’s natural ability to 
recognize and attack cancer cells.
In general, scientists agree that an 
effective treatment for GBM must have 
several components. These include being 
highly selective to avoid damage to 
non-cancerous brain tissue and efﬁ  cient 
cell killing, preferably by simultaneous 
activation of multiple killing mechanisms. 
Moreover, as it is unlikely that any 
treatment can target all cancer cells, it 
will be necessary to achieve a cancer-
speciﬁ  c “bystander effect,” which kills 
neighboring tumors but not normal cells. 
Alexander Levitzki and colleagues 
tested a therapy that tries to meet all 
these criteria by taking advantage of the 
frequent (50%–70%) overexpression of 
the epidermal growth factor receptors 
(EGFRs) in GBM. In those tumors, the 
number of EGFRs on tumor cells is 
10–20 times higher than that on non-
tumor cells. Based on this difference, 
they reasoned that any treatment 
that targets the EGFR would reach 
predominantly tumor cells. They built 
a non-viral delivery vehicle that could 
center in on cells expressing the EGFR 
and trigger internalization of the 
complex of the receptor and the bound 
vehicle. As a “toxic cargo,” Levitzki and 
colleagues selected double-stranded 
RNA (polyinosine-cytosine, poly IC). 
Double-stranded RNA doesn’t occur 
naturally in eukaryotic cells, but is often 
associated with viral infections. To protect 
themselves against “viral takeover,” 
multicellular organisms have evolved 
efﬁ  cient defense mechanisms that result 
in apoptotic death of cells that contain 
dsRNA. 
The team found that the poly IC 
induced rapid apoptosis in the target 
cells in vitro and in glioblastomas in mice. 
The therapy induced complete regression 
of pre-established intracranial tumors 
in nude mice, with no obvious adverse 
toxic effects on normal brain tissue. And 
one year later, the treated mice were still 
disease-free and healthy.
EGFR overexpression is common in 
other cancer types as well, and further 
in vivo experiments in mice showed that 
non-viral delivery of poly IC completely 
eliminated pre-established breast cancer 
and adenocarcinoma xenografts derived 
from EGFR overexpressing cancer cell 
lines, suggesting that the strategy might 
be applicable to other cancer types. 
The researchers also suggest that the 
principle of ligand-guided delivery 
of dsRNA at a particular receptor 
that is overexpressed and undergoes 
endocytosis might be applicable in a 
range of cancers.
Experience tells that curing cancer in 
mice is easy and curing cancer in humans 
is hard. It is too early to tell whether this 
is one of the few approaches that will still 
look promising after the next round of 
tests. In light of the encouraging results 
of this study and the lack of effective 
treatments for GBM, however, Robert Weil 
(DOI: 10.1371/journal.pmed.0030031) 
suggests in an accompanying 
commentary that the use of dsRNA 
delivered by non-viral vectors deserves to 
be fast-tracked to the clinic. 
Shir A, Ogris M, Wagner E, Levitzki A (2006) 
EGF receptor-targeted synthetic double-
stranded RNA eliminates glioblastoma, 
breast cancer, and adenocarcinoma 
tumors in mice. DOI: 10.1371/journal.
pmed.0030006
New Approach to Combat Glioblastoma Shows Promise in Preclinical Studies 
DOI: 10.1371/journal.pmed.0030034
DOI: 10.1371/journal.pmed.0030034.g001
Glioblastoma in treated (right) and control 
(left) animals.
To further examine a possible 
connection between placental 
microtransfusions and HIV MTCT, Jesse 
Kwiek and colleagues have taken 
advantage of a recently developed 
assay that provides a surrogate measure 
for placental microtransfusions, based 
on the amount of placental alkaline 
phosphatase (PLAP) in umbilical cord 
blood. PLAP is a large maternal enzyme 
that cannot cross the intact placental 
barrier. Infants produce very low levels 
of PLAP, and amounts found in umbilical 
cord blood are thought to result from 
leakage of maternal protein into the 
fetal circulation, caused by placental 
microtransfusions. 
The researchers measured PLAP 
activity in umbilical cord blood 
as an indicator of maternal–fetal 
microtransfusions, and related this to 
risk of MTCT in a case-cohort study 
of mothers who were HIV-positive 
in Malawi. In the study, 149 women 
randomly selected from a larger cohort 
of pregnant women infected with HIV 
served as a reference group for 36 
cases of prenatal MTCT and 43 cases of 
perinatal MTCT. The researchers saw no 
correlation between PLAP levels and 
prenatal MTCT. However, among the 
cases of perinatal transmission in women 
who had vaginal deliveries, elevated 
PLAP levels were associated with higher 
transmission risks. The connection 
was also seen after adjusting for some 
potential confounding factors such as HIV 
viral RNA load and chorioamnionitis. 
While these are preliminary results and 
many questions remain, the reviewers felt 
that the design of the study enabled an 
efﬁ  cient ﬁ  rst test of the maternal–fetal 
microtransfusion hypothesis of MCTC. 
As such, it should encourage other 
researchers to look at this issue in their 
datasets. If a connection between 
microtransfusions and transmission 
is conﬁ  rmed, it might help to improve 
the timing of short-term prophylaxis 
regimens and possibly lead to the 
development of new strategies for 
preventing MTCT of HIV. 
Kwiek JJ, Mwapasa V, Milner DA Jr, Alker 
AP, Millern WC, et al. (2006) Maternal–fetal 
microtransfusions and HIV-1 mother-to-
child transmission in Malawi. DOI: 10.1371/
journal.pmed.0030010
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